NLS Pharmaceutics Announces Publication Of New Patent Application For Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists With The World Intellectual Property Organization
NLS Pharmaceutics Announces Publication Of New Patent Application For Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists With The World Intellectual Property Organization
NLS药品宣布与世界知识产权组织共同发表了一份新的专利申请，申请了下一代双非磺酰胺觉醒素受体激动剂。
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced the publication of the latest patent application (PCT/WO2024115797) by Aexon Labs with the World Intellectual Property Organization (WIPO). The patent will be used by NLS pursuant to its existing and previously announced license agreement with Aexon Labs.
瑞士临床生物制药公司NLS Pharmaceutics Ltd.（纳斯达克：NLSP）（NLSPW），致力于为罕见和复杂的中枢神经系统疾病开拓疗法，今天宣布，根据其现有和先前宣布的与Aexon Labs的许可协议，公司将使用由Aexon Labs向世界知识产权组织（WIPO）提交的最新专利申请（PCT/WO2024115797）的专利。